Method of Detecting Cancer
AssigneeSienna Cancer Diagnostics Inc.
InventorsMinesh Lalla, Fabio Turatti, Sharyn Wilson
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods for resolving an inconclusive cytological assessment of clinically relevant cells in a sample obtained from a patient based on the cytological detection of an antibody binding to a diagnostic protein in the clinically relevant cells in the sample.
Claims18
A method of resolving an inconclusive cytological assessment of clinically relevant cells in a sample obtained from a patient, the method comprising contacting cells from the sample with an anti-telomerase antibody and performing a cytological assessment of the cells to detect binding of the antibody to clinically relevant cells, wherein binding of the antibody to clinically relevant cells indicates the presence of malignant cells.
A method of determining whether a subject has cancer when a cytological assessment of cell morphology is inconclusive for the cancer, the method comprising:
- i) contacting a cell sample from the subject with an anti-telomerase antibody;
- ii) performing a cytological assessment of the cell sample to detect binding of the antibody to clinically relevant cells in the sample;
- wherein binding of the antibody to one or more clinically relevant cells in the sample indicates that the subject has cancer.
A method of determining whether a subject has cancer, the method comprising:
- i) performing a cytological assessment of cell morphology on a cell sample from the subject to determine the morphology of one or more clinically relevant cells in the sample;
- ii) contacting a cell sample from the subject with an anti-telomerase antibody and performing a cytological assessment of the cell sample to detect binding of the antibody to clinically relevant cells in the sample;
- wherein when the cytological assessment of cell morphology is inconclusive for the cancer, binding of the antibody to one or more clinically relevant cells indicates that the subject has cancer.
A method of resolving an inconclusive cytological assessment of bladder epithelial cells in a urine sample obtained from a patient, the method comprising contacting epithelial cells from the sample with an anti-telomerase antibody and performing a cytological assessment of the epithelial cells to detect binding of the antibody to the epithelial cells, wherein binding of the antibody to the epithelial cells indicates the presence of malignant cells.
A method of determining whether a subject has bladder cancer when a cytological assessment of bladder epithelial cell morphology that is inconclusive for bladder cancer, the method comprising:
- i) contacting a sample of bladder epithelial cells from the subject with an anti-telomerase antibody;
- ii) performing a cytological assessment of the bladder epithelial cells to detect binding of the antibody to the bladder epithelial cells;
- wherein binding of the antibody to one or more bladder epithelial cells in the sample indicates that the subject has cancer.
A method of determining whether a subject has bladder cancer, the method comprising:
- i) performing a cytological assessment of cell morphology on a sample of bladder epithelial cells from the subject to determine the morphology of one or more bladder epithelial cells in the sample;
- ii) contacting a sample of bladder epithelial cells from the subject with an anti-telomerase antibody and performing a cytological assessment of the bladder epithelial cells to detect binding of the antibody to the bladder epithelial cells;
- wherein when the cytological assessment of cell morphology is inconclusive for bladder cancer, binding of the antibody to one or more bladder epithelial cells indicates that the subject has cancer.
Dependencies are inferred from the claim text.